These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1332623)

  • 1. [DNA topoisomerase inhibitor].
    Sugiura T; Ariyoshi Y
    Gan To Kagaku Ryoho; 1992 Nov; 19(13):2140-5. PubMed ID: 1332623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Topoisomerase inhibitors developing in Japan].
    Furue H
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camptothecin analogues in the treatment of non-small cell lung cancer.
    Ardizzoni A
    Lung Cancer; 1995 Apr; 12 Suppl 1():S177-85. PubMed ID: 7551927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topotecan demonstrates significant activity in recurrent small-cell lung cancer.
    Oncology (Williston Park); 1996 Jan; 10(1):111. PubMed ID: 8924362
    [No Abstract]   [Full Text] [Related]  

  • 5. Topoisomerase I inhibitors in the treatment of colorectal cancer.
    Rothenberg ML; Blanke CD
    Semin Oncol; 1999 Dec; 26(6):632-9. PubMed ID: 10606256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
    Fukuoka M; Niitani H; Suzuki A; Motomiya M; Hasegawa K; Nishiwaki Y; Kuriyama T; Ariyoshi Y; Negoro S; Masuda N
    J Clin Oncol; 1992 Jan; 10(1):16-20. PubMed ID: 1309380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of topotecan in metastatic non-small-cell lung cancer.
    Lynch TJ; Kalish L; Strauss G; Elias A; Skarin A; Shulman LN; Posner M; Frei E
    J Clin Oncol; 1994 Feb; 12(2):347-52. PubMed ID: 8113842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical trials of topoisomerase inhibitors.
    Saijo N
    Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.
    Tsakalozou E; Adane ED; Liang Y; Arnold SM; Leggas M
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):45-54. PubMed ID: 24807458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
    Bonneterre J
    Bull Cancer; 1995 Aug; 82(8):623-8. PubMed ID: 7492818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
    Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
    Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials with the topoisomerase I inhibitors.
    Burris HA; Rothenberg ML; Kuhn JG; Von Hoff DD
    Semin Oncol; 1992 Dec; 19(6):663-9. PubMed ID: 1334279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
    Taguchi T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1574-8. PubMed ID: 1651685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
    Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan demonstrates significant activity in small-cell lung cancer.
    Oncology (Williston Park); 1996 Mar; 10(3):422-3. PubMed ID: 8820456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.